Abstract
Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds. The overall seroprevalence increased from 73.9% in round one to 90.7% in round two and 92.9% in round three. Among seropositive rural participants in round one, 98.2% remained positive in round two, and this percentage remained stable in urban and tribal areas in round three. The results showed high antibody prevalence that increased over time and was not different based on area, age group, or sex. Vaccinated individuals had higher antibody prevalence, and nearly all participants had antibody positivity for up to six months.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a research grant (Ref No: 2020/1085497, Purchase Order: 202630166) from the WHO Country Office, New Delhi 110016, India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Approval and Consent to participate The study received ethical clearance from all five participating institutes (Letter No. For AIIMS, New Delhi: IEC-959/04.09.2020, AIIMS Bhubaneswar: T/EMF/CM&FM/20/44, JIPMER Puducherry: JIP/IEC/2020/248, AIIMS Gorakhpur: IHEC/AIIMS-GKP/BMR/01/22, Agartala: F.4(5-234)/AGMC/ACADEMIC/IEC MEETING). Written informed consent, assent and consent from the parents/guardians for the participants under the legal age of giving consent was obtained from all the participants as per ICMR guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
* After first and corresponding author, all others authors sequence is arranged alphabetically
Biographical Sketch of first author: Dr. Puneet Misra is Professor of Community Medicine at the All India Institute of Medical Sciences having over twenty years of experience as Physician, Researcher, Teacher, Epidemiologist and Public Health professional. His area of specialties are Public Health, Vaccine Trial, Clinical Trials, Epidemiologist, Yoga, chronic disease, life style medicine etc.
Data Availability
The data is kept with the repository of the corresponding author. Due to the confidentiality, it is available upon reasonable request to the corresponding author.
Abbreviations
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus-2
- WHO
- World Health Organization
- COVID
- Coronavirus Disease
- ELISA
- Enzyme-linked Immunosorbent Assay
- AIIMS
- All India Institute of Medical Sciences
- NCR
- Delhi National Capital Region
